The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster

Figures & data

Figure 1 (A) Comparison of total anti-SARS-CoV-2 antibodies level between patients after Pfizer and AstraZeneca vaccination. The data are presented as median (minimum - maximum). (B) Comparison of total anti-SARS-CoV-2 antibodies level in groups of women and men after Pfizer and AstraZeneca vaccination. The data are presented as median (minimum - maximum). (C) Comparison of total anti-SARS-CoV-2 antibodies level in groups of patients before and after the age of 50 after Pfizer and AstraZeneca vaccination. The data are presented as median (minimum - maximum). (D) Comparison of total anti-SARS-CoV-2 antibodies level in groups of patients with normal and increased BMI after Pfizer and AstraZeneca vaccination. The data are presented as median (minimum - maximum). (E) Comparison of total anti-SARS-CoV-2 antibodies level in groups of patients with and no post-vaccination symptoms after Pfizer and AstraZeneca vaccination. The data are presented as median (minimum - maximum). (F) Comparison of total anti-SARS-CoV-2 antibodies level in groups of patients with and without history of COVID 19 after Pfizer and AstraZeneca vaccination. The data are presented as median (minimum - maximum). (G) Comparison of total anti-SARS-CoV-2 antibodies level in groups of patients with and without coexisting diseases after Pfizer and AstraZeneca vaccination. The data are presented as median (minimum - maximum).

Figure 2 Heat map of correlation of total anti-SARS-CoV2 antibodies in patients after Pfizer vaccination with chosen clinical parameters.

Figure 3 Heat map of correlation of total anti-SARS-CoV2 antibodies after AstraZeneca vaccination with chosen clinical parameters.

Table 1 Characteristics of Study Group

Parameter	Number of Persons (%) Who Were Primed with Two Doses of BNT162B2 (n=114)	Number of Persons (%) Who Were Primed with Two Doses of ChAdOx1-S (n=78)
Age, years
≤50	48 (42%)	27 (31%)
>50	66 (58%)	51 (69%)
Sex
Female	84 (74%)	57 (73%)
Male	30 (26%)	21(27%)
History of COVID-19
Present	60 (53%)	57 (73%)
Absent	54 (47%)	21(27%)
BMI, kg/m^2
≤ 24.9	66 (58%)	30 (38%)
>24.9	48 (42%)	48 (62%)
Other diseases
Present	69 (60%)	48 (62%)
Absent	45 (40%)	30 (38%)
Post-vaccination symptoms
Present	57 (50%)	51 (65%)
Absent	57 (50%)	27 (35%)

Table 2 Comparisions of Results Anti-SARS-CoV-2S Antibodies Concentration in Both Group of Residents with p value

Parameter	Persons Who Were Primed with Two Doses of BNT162B2 (n=114)			Persons Who Were Primed with Two Doses of ChAdOx1-S (n=78)			p value
	Median	Q1	Q3	Median	Q1	Q3
Age, years
≤50	14,795	11,231	19,656	10,368	8501	13,047	0.0189
>50	17,278	11,384	24,791	11,325	8659	18,983	0.0495
Sex
Female	17,154	11,605	23,436	11,305	9434	18,983	0.0111
Male	12,946	10,195	18,891	12,986	4035	18,965	0.8868
History of COVID-19
Present	14,415	11,126	23,436	11,117	7568	14,644	0.0400
Absent	17,154	12,620	22,284	17,712	11,325	23,879	0.8476
BMI, kg/m^2
≤24.9	17,154	12,620	24,639	13,047	8968	19,146	0.0375
>24.9	14,415	10,467	19,656	11,216	9086	16,591	0.5455
Other diseases
Present	16,710	11,461	24,639	10,840	8035	16,146	0.0059
Absent	16,676	10,504	21,786	13,936	10,510	19,745	0.9012
Post-vaccination symptoms
Present	15,637	12,038	21,499	11,325	9147	16,805	0.0434
Absent	16,923	11,151	23,986	11,305	6591	19,309	0.1683

Table 3 Multiple Regression Analysis of the Level of Anti-SARS-CoV-2S Antibodies

Parameter	Anti- SARS-CoV-2s Antibodies
	Estimate	95% CI	P value
Sex	−1562	−5485 to 2362	0.4286
Age	1090	−2456 to 4636	0.5405
Coexistence diseases	94,92	−3574 to 3764	0.9588
Vaccine type	−3582	−7086 to −78,62	0.0452